Results 11 to 20 of about 310,703 (307)

Individualized interactomes for network-based precision medicine in hypertrophic cardiomyopathy with implications for other clinical pathophenotypes

Nature Communications, 2021
Progress in precision medicine is limited by insufficient knowledge of transcriptomic or proteomic features in involved tissues that define pathobiological differences between patients.
Bradley A. Maron, Rui-Sheng Wang, Sergei Shevtsov, Stavros G. Drakos, Elena Arons, Omar Wever-Pinzon, Gordon S. Huggins, Andriy O. Samokhin, William M. Oldham, Yasmine Aguib, Magdi H. Yacoub, Ethan J. Rowin, Barry J. Maron, Martin S. Maron, Joseph Loscalzo   +14 more
doaj   +2 more sources

Self- and Goal-Directed Valsalva Maneuver vs Exercise in Eliciting Left Ventricular Outflow Tract Obstruction [PDF]

JACC: Advances
Background: In symptomatic patients with hypertrophic cardiomyopathy (HCM), eliciting left ventricular outflow tract obstruction (LVOTO) is critical. A self-directed Valsalva (SDV) and exercise (EX) are frequent tools used to unmask obstruction in HCM ...
Aakash Bavishi, MD, MSCI, John Fritzlen, MD, Kutaiba Nazif, DO, Marybeth Soutar, MS, Margaret Kurnides, RDCS, Heather Speer, RDCS, Glenda Oyarce, RCS, Karen Richards, RN, Cara Flahive, RN, Matthew W. Martinez, MD   +9 more
doaj   +2 more sources

Characteristics and Outcomes of Elderly Patients With Hypertrophic Cardiomyopathy

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2021
Background We report characteristics and outcomes of elderly patients with hypertrophic cardiomyopathy (HCM) with basal septal hypertrophy and dynamic left ventricular outflow tract obstruction.
Alaa Alashi, Nicholas G. Smedira, Zoran B. Popovic, Agostina Fava, Maran Thamilarasan, Samir R. Kapadia, Per Wierup, Harry M. Lever, Milind Y. Desai   +8 more
doaj   +1 more source

Outcomes in Guideline‐Based Class I Indication Versus Earlier Referral for Surgical Myectomy in Hypertrophic Obstructive Cardiomyopathy

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2021
Background In patients with obstructive hypertrophic cardiomyopathy, surgical myectomy (SM) is indicated for severe symptoms. We sought to compare long‐term outcomes of patients with obstructive hypertrophic cardiomyopathy where SM was based on guideline‐
Alaa Alashi, Nicholas G. Smedira, Kevin Hodges, Zoran B. Popovic, Maran Thamilarasan, Per Wierup, Harry M. Lever, Milind Y. Desai   +7 more
doaj   +1 more source

Efficient in vivo genome editing prevents hypertrophic cardiomyopathy in mice

Nature Medicine, 2023
Dominant missense pathogenic variants in cardiac myosin heavy chain cause hypertrophic cardiomyopathy (HCM), a currently incurable disorder that increases risk for stroke, heart failure and sudden cardiac death.
D. Reichart, Gregory A. Newby, H. Wakimoto, M. Lun, J. Gorham, Justin J. Curran, Aditya Raguram, D. DeLaughter, D. Conner, Júlia D C Marsiglia, Sajeev Kohli, Lukas Chmatal, D. Page, N. Zabaleta, L. Vandenberghe, David R. Liu, J. Seidman, C. Seidman   +17 more
semanticscholar   +1 more source

Mavacamten: a first-in-class myosin inhibitor for obstructive hypertrophic cardiomyopathy

European Heart Journal, 2023
Graphical Abstract Graphical Abstract The path to treatment of obstructive hypertrophic cardiomyopathy. (Top left) Haemodynamic observations demonstrated. Left ventricular (LV) obstruction and symptoms related to LV hypertrophy.
E. Braunwald, S. Saberi, T. Abraham, Perry M. Elliott, I. Olivotto   +4 more
semanticscholar   +1 more source

Effect of Mavacamten on Chinese Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy

JAMA cardiology, 2023
Key Points Question What is the effect of treatment with mavacamten on Chinese patients with symptomatic obstructive hypertrophic cardiomyopathy? Findings In this phase 3 randomized clinical trial of 81 patients, mavacamten significantly improved ...
Z. Tian, Liwen Li, Xiaoyan Li, Jian’an Wang, Qing Zhang, Zhan-hui Li, Daoquan Peng, Ping‐Ping Yang, Wei Ma, Fang-Ming Wang, Wei Jin, Xiang Cheng, Jing Sun, Yiqun Fu, Chengjian Lyu, Shuyang Zhang   +15 more
semanticscholar   +1 more source

Outcomes in Patients With Obstructive Hypertrophic Cardiomyopathy and Concomitant Aortic Stenosis Undergoing Surgical Myectomy and Aortic Valve Replacement

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2021
Background Hypertrophic cardiomyopathy (HCM) and aortic stenosis can cause obstruction to the flow of blood out of the left ventricular outflow tract into the aorta, with obstructive HCM resulting in dynamic left ventricular outflow tract obstruction and
Milind Y. Desai, Alaa Alashi, Zoran B. Popovic, Per Wierup, Brian P. Griffin, Maran Thamilarasan, Douglas Johnston, Lars G. Svensson, Harry M. Lever, Nicholas G. Smedira   +9 more
doaj   +1 more source

Hypertrophic Cardiomyopathy [PDF]

Cardiac Electrophysiology Clinics, 2010
Hypertrophic cardiomyopathy is a myocardial disease characterized by myocardial hypertrophy, disorganization of cardiac myocytes, and fibrosis. Twenty-five percent of patients have a dynamic left ventricular outflow tract gradient caused by the combined effects of rapid ventricular ejection, a narrowed outflow tract, and systolic anterior motion of the
Christopher, Critoph, Perry, Elliott
openaire   +4 more sources

Predictors of cardiac involvement and survival in patients with primary systemic light-chain amyloidosis: roles of the clinical, chemical, and 3-D speckle tracking echocardiography parameters

BMC Cardiovascular Disorders, 2021
Background Light-chain (AL) amyloidosis is the most common type of systemic amyloidosis with poor prognosis. Currently, the predictors of cardiac involvement and prognostic staging systems are primarily based on conventional echocardiography and ...
Changhui Lei, Xiaoli Zhu, David H. Hsi, Jing Wang, Lei Zuo, Shengjun Ta, Qianli Yang, Lei Xu, Xueli Zhao, Yan Wang, Shiren Sun, Liwen Liu   +11 more
doaj   +1 more source